Kiniksa Pharmaceuticals International, plc
KNSA
$31.98
$1.725.68%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 56.18% | 59.45% | 56.60% | 54.41% | 20.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.18% | 59.45% | 56.60% | 54.41% | 20.69% |
| Cost of Revenue | 95.97% | 107.09% | 110.41% | 92.76% | 101.66% |
| Gross Profit | 32.44% | 33.65% | 29.77% | 37.01% | -2.64% |
| SG&A Expenses | 16.44% | 24.30% | 29.81% | 36.96% | 38.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.23% | 49.55% | 58.69% | 53.12% | 50.97% |
| Operating Income | 116.27% | 48.26% | -81.04% | -36.43% | -172.17% |
| Income Before Tax | 179.14% | 70.73% | -117.10% | -36.39% | -141.94% |
| Income Tax Expenses | 221.58% | 135.21% | 122.91% | -37.46% | 95.86% |
| Earnings from Continuing Operations | 146.82% | -295.95% | -406.68% | -35.51% | -104.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 146.82% | -295.95% | -406.68% | -35.51% | -104.42% |
| EBIT | 116.27% | 48.26% | -81.04% | -36.43% | -172.17% |
| EBITDA | 123.47% | 49.78% | -92.17% | -45.01% | -163.03% |
| EPS Basic | 141.83% | -290.38% | -403.66% | -30.39% | -104.34% |
| Normalized Basic EPS | 174.55% | 71.14% | -111.82% | -34.40% | -141.32% |
| EPS Diluted | 125.62% | -320.18% | -424.39% | -24.75% | -104.79% |
| Normalized Diluted EPS | 163.39% | 68.02% | -111.25% | -33.57% | -142.35% |
| Average Basic Shares Outstanding | 2.81% | 2.34% | 1.95% | 1.53% | 1.25% |
| Average Diluted Shares Outstanding | 4.80% | 2.13% | 0.51% | 1.09% | 0.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |